MA47509A - Traitement par anticorps anti-pd-l1 du cancer de la vessie - Google Patents

Traitement par anticorps anti-pd-l1 du cancer de la vessie

Info

Publication number
MA47509A
MA47509A MA047509A MA47509A MA47509A MA 47509 A MA47509 A MA 47509A MA 047509 A MA047509 A MA 047509A MA 47509 A MA47509 A MA 47509A MA 47509 A MA47509 A MA 47509A
Authority
MA
Morocco
Prior art keywords
bladder cancer
antibody treatment
antibody
treatment
bladder
Prior art date
Application number
MA047509A
Other languages
English (en)
French (fr)
Inventor
yong Ben
John Andrew Blake-Haskins
Mohammed Dar
Ashok Gupta
Tony Ho
Robert Iannone
Xiaoping Jin
John Kurland
Shannon Morris
Marlon Rebelatto
Li Shi
Jill Walker
Magdalena Zajac
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA47509A publication Critical patent/MA47509A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA047509A 2017-02-16 2018-02-16 Traitement par anticorps anti-pd-l1 du cancer de la vessie MA47509A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16

Publications (1)

Publication Number Publication Date
MA47509A true MA47509A (fr) 2019-12-25

Family

ID=63169615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047509A MA47509A (fr) 2017-02-16 2018-02-16 Traitement par anticorps anti-pd-l1 du cancer de la vessie

Country Status (12)

Country Link
US (2) US20190359715A1 (enExample)
EP (1) EP3582805A4 (enExample)
JP (2) JP2020507596A (enExample)
KR (3) KR20230145547A (enExample)
CN (2) CN110290803A (enExample)
AU (2) AU2018221822A1 (enExample)
CA (1) CA3052652A1 (enExample)
EA (1) EA201991870A1 (enExample)
IL (3) IL320916A (enExample)
MA (1) MA47509A (enExample)
SG (1) SG11201907211TA (enExample)
WO (1) WO2018152415A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900544T1 (it) * 2014-05-13 2019-11-13 Medimmune Ltd Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
IL320916A (en) * 2017-02-16 2025-07-01 Medimmune Llc Bladder cancer treatment with anti-PD-L1 antibody
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CN115667552A (zh) * 2020-05-21 2023-01-31 阿斯利康(瑞典)有限公司 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
SMT201900544T1 (it) * 2014-05-13 2019-11-13 Medimmune Ltd Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
JP7144935B2 (ja) * 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
EP3448428A4 (en) * 2016-04-25 2019-11-27 Medimmune, LLC COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
IL320916A (en) * 2017-02-16 2025-07-01 Medimmune Llc Bladder cancer treatment with anti-PD-L1 antibody

Also Published As

Publication number Publication date
CA3052652A1 (en) 2018-08-23
SG11201907211TA (en) 2019-09-27
JP2024038034A (ja) 2024-03-19
KR20250025517A (ko) 2025-02-21
IL302777A (en) 2023-07-01
CN110290803A (zh) 2019-09-27
KR20230145547A (ko) 2023-10-17
AU2018221822A1 (en) 2019-09-26
KR20190117014A (ko) 2019-10-15
IL320916A (en) 2025-07-01
EA201991870A1 (ru) 2020-02-12
US20220332828A1 (en) 2022-10-20
AU2025201227A1 (en) 2025-03-13
JP2020507596A (ja) 2020-03-12
EP3582805A4 (en) 2021-03-10
EP3582805A1 (en) 2019-12-25
US20190359715A1 (en) 2019-11-28
IL268460A (en) 2019-09-26
WO2018152415A1 (en) 2018-08-23
CN118001389A (zh) 2024-05-10

Similar Documents

Publication Publication Date Title
EP3341413A4 (en) THERAPY AND IMAGING FOR CANCER AND STROKE ON MONOCLONAL ANTI-DESPR ANTIBODIES
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3441086A4 (en) MONOCLONAL ANTI-PD-1 ANTIBODY
EP3532489A4 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
EP3621592A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA50409A (fr) Polythérapies pour le traitement du cancer
MA47408A (fr) Traitement du cancer
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
EP3383915A4 (en) PD-1 ANTIBODY
EP3610026A4 (en) METHOD OF TREATMENT OF BLADDER CANCER
MA46361A (fr) Traitement du cancer de la prostate
EP3383497A4 (en) NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES
MA52627A (fr) Traitement du cancer
EP3820461A4 (en) METHODS OF TREATMENT OF CANCER
EP3746120A4 (en) ANTI-PD-1 ANTIBODY
EP3733175A4 (en) THERAPEUTICS AGAINST CANCER
PL3679069T3 (pl) Przeciwciała przydatne w diagnostyce nowotworów
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
IL281845A (en) Combination therapy for the treatment of cancer